Celgene, Bristol-Myers Squibb Question Blue Cross Unit’s Recusal Amid Antitrust Litigation

Drug giants Celgene and Bristol-Myers Squibb relayed their discontent on Tuesday concerning the timing of an unexpected recusal by a Blue Cross unit from a New Jersey federal court antitrust litigation. The litigation accuses the pharmaceutical manufacturers of obstructing the entry of generic competitors for top-tier cancer treatments. The Blue Cross unit’s sudden decision to step-down as a plaintiff has resulted in raised eyebrows across the sector, creating unease that the insurer might neglect its discovery obligations. More details can be found in the referenced Law360 report.